Seeking to develop a new class of cancer therapy that causes tumours to simply die, using proprietary peptides.

Summary

Pronec Ltd is seeking to develop a cancer therapy that causes tumours to simply die, using proprietary peptides. The Company’s approach aims to causes necrosis (cell death) of a wide range of tumour cell lines in culture, without affecting normal cell lines.

Product

Life Sciences SEIS

Sector

Drug discovery

Status

Closed

HMRC

Advanced Assurance